A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Latest Information Update: 15 Jan 2025
At a glance
- Drugs Parsaclisib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
Most Recent Events
- 01 Dec 2024 Results reporting long-term data from this trial published in the American Journal of Hematology
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 23 Oct 2023 Planned End Date changed from 8 Sep 2023 to 29 Mar 2024.